Abstract
There is an unmet need for new strategies to prevent or postpone the development of diabetic kidney disease. The pathophysiology of this condition includes as a central mechanism an imbalance between the excessive production of reactive oxygen species (ROS) and inadequate anti-oxidant defense. Reduction of ROS is therefore an interesting therapeutic target that warrants further investigation. Herein, we review the drivers of oxidative stress in diabetic kidney disease including NADPH oxidases, mitochondrial ROS production, xanthine oxidase, cytochrome P450, uncoupled eNOS and lipoxygenase. Secondly, the role of anti-oxidative mechanisms in diabetic kidney disease is discussed including the role of the kelch-like ECH-associated protein 1- nuclear factor erythroid 2-related factor 2, lipoxin, oral anti-oxidants and glutathione peroxidase-1. We will also review data supporting the concept that the beneficial renal effects of anti-diabetic drugs that target the glucagon-like peptide 1 receptor and the sodium glucose transporter 2 are, at least in part, due to their impact on oxidative stress in diabetic kidney disease. In the present article we critically evaluate both preclinical studies with cell culture experiments and animal models of diabetic kidney disease as well as covering the current findings from clinical studies addressing targeted interventions towards these pathways.
Similar content being viewed by others
References
Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58(7):1651–1658. https://doi.org/10.2337/db08-1543
US Renal Data System (2019) Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2019.09.002
Tsalamandris C, Allen TJ, Gilbert RE et al (1994) Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 43(5):649–655. https://doi.org/10.2337/diab.43.5.649
Pugliese G, Penno G, Natali A et al (2020) Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. J Nephrol 33(1):9–35. https://doi.org/10.1007/s40620-019-00650-x
Viazzi F, Russo GT, Ceriello A et al (2019) Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals. J Nephrol 32(4):517–525. https://doi.org/10.1007/s40620-018-00561-3
Diabetes Control Complications Trial Research Group, Nathan DM, Genuth S et al (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986. https://doi.org/10.1056/NEJM199309303291401
Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28(2):103–117. https://doi.org/10.1016/0168-8227(95)01064-k
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329(20):1456–1462. https://doi.org/10.1056/NEJM199311113292004
Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860. https://doi.org/10.1056/NEJMoa011303
Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K (2016) Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal 25(12):657–684. https://doi.org/10.1089/ars.2016.6664
Jha JC, Ho F, Dan C, Jandeleit-Dahm K (2018) A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clin Sci (Lond) 132(16):1811–1836. https://doi.org/10.1042/CS20171459
Gray SP, Di Marco E, Okabe J et al (2013) NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127(18):1888–1902. https://doi.org/10.1161/CIRCULATIONAHA.112.132159
Babelova A, Avaniadi D, Jung O et al (2012) Role of Nox4 in murine models of kidney disease. Free Radic Biol Med 53(4):842–853. https://doi.org/10.1016/j.freeradbiomed.2012.06.027
Jha JC, Gray SP, Barit D et al (2014) Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol 25(6):1237–1254. https://doi.org/10.1681/ASN.2013070810
Jha JC, Thallas-Bonke V, Banal C et al (2016) Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Diabetologia 59(2):379–389. https://doi.org/10.1007/s00125-015-3796-0
Gorin Y, Cavaglieri RC, Khazim K et al (2015) Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol 308(11):F1276–1287. https://doi.org/10.1152/ajprenal.00396.2014
You YH, Quach T, Saito R, Pham J, Sharma K (2016) Metabolomics reveals a key role for fumarate in mediating the effects of NADPH oxidase 4 in diabetic kidney disease. J Am Soc Nephrol 27(2):466–481. https://doi.org/10.1681/ASN.2015030302
Gray SP, Di Marco E, Kennedy K et al (2016) reactive oxygen species can provide atheroprotection via NOX4-dependent inhibition of inflammation and vascular remodeling. Arterioscler Thromb Vasc Biol 36(2):295–307. https://doi.org/10.1161/ATVBAHA.115.307012
Holterman CE, Thibodeau JF, Towaij C et al (2014) Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J Am Soc Nephrol 25(4):784–797. https://doi.org/10.1681/ASN.2013040371
Jha JC, Dai A, Holterman CE et al (2019) Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse. Diabetologia 62(9):1712–1726. https://doi.org/10.1007/s00125-019-4924-z
Jha JC, Banal C, Okabe J et al (2017) NADPH oxidase nox5 accelerates renal injury in diabetic nephropathy. Diabetes 66(10):2691–2703. https://doi.org/10.2337/db16-1585
Guzik TJ, Chen W, Gongora MC et al (2008) Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 52(22):1803–1809. https://doi.org/10.1016/j.jacc.2008.07.063
Deliyanti D, Alrashdi SF, Touyz RM et al (2020) Nox (NADPH Oxidase) 1, Nox4, and Nox5 promote vascular permeability and neovascularization in retinopathy. Hypertension 75(4):1091–1101. https://doi.org/10.1161/HYPERTENSIONAHA.119.14100
Eid S, Hayes JM, Guo KAI et al (2018) NOX, NOX, Are you here? The emerging role of NOX5 in diabetic neuropathy. Diabetes 67(Supplement 1):30-LB. https://doi.org/10.2337/db18-30-LB
Sedeek M, Gutsol A, Montezano AC et al (2013) Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) 124(3):191–202. https://doi.org/10.1042/CS20120330
Sedeek M, Callera G, Montezano A et al (2010) Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 299(6):F1348–1358. https://doi.org/10.1152/ajprenal.00028.2010
Gray SP, Jha JC, Kennedy K et al (2017) Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia 60(5):927–937. https://doi.org/10.1007/s00125-017-4215-5
ten Freyhaus H, Huntgeburth M, Wingler K et al (2006) Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 71(2):331–341. https://doi.org/10.1016/j.cardiores.2006.01.022
Cha JJ, Min HS, Kim KT et al (2017) APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest 97(4):419–431. https://doi.org/10.1038/labinvest.2017.2
Nishikawa T, Edelstein D, Du XL et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404(6779):787–790. https://doi.org/10.1038/35008121
Coughlan MT, Sharma K (2016) Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease. Kidney Int 90(2):272–279. https://doi.org/10.1016/j.kint.2016.02.043
Herlein JA, Fink BD, O’Malley Y, Sivitz WI (2009) Superoxide and respiratory coupling in mitochondria of insulin-deficient diabetic rats. Endocrinology 150(1):46–55. https://doi.org/10.1210/en.2008-0404
Coughlan MT, Nguyen TV, Penfold SA et al (2016) Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin Sci (Lond) 130(9):711–720. https://doi.org/10.1042/CS20150838
Prabhakar SS (2004) Role of nitric oxide in diabetic nephropathy. Semin Nephrol 24(4):333–344. https://doi.org/10.1016/j.semnephrol.2004.04.005
Noiri E, Satoh H, Taguchi J et al (2002) Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 40(4):535–540. https://doi.org/10.1161/01.hyp.0000033974.57407.82
Zhao HJ, Wang S, Cheng H et al (2006) Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 17(10):2664–2669. https://doi.org/10.1681/ASN.2006070798
Satoh M, Fujimoto S, Haruna Y et al (2005) NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288(6):F1144–1152. https://doi.org/10.1152/ajprenal.00221.2004
Wenzel P, Schulz E, Oelze M et al (2008) AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med 45(5):619–626. https://doi.org/10.1016/j.freeradbiomed.2008.05.009
Wenzel P, Daiber A, Oelze M et al (2008) Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 198(1):65–76. https://doi.org/10.1016/j.atherosclerosis.2007.10.003
Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH (2009) Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 58(7):1668–1671. https://doi.org/10.2337/db09-0014
Kosugi T, Nakayama T, Heinig M et al (2009) Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 297(2):F481–488. https://doi.org/10.1152/ajprenal.00092.2009
Komers R, Xu B, Schneider J, Oyama TT (2016) Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes. Br J Pharmacol 173(17):2573–2588. https://doi.org/10.1111/bph.13527
Beddhu S, Filipowicz R, Wang B et al (2016) A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy. Can J Kidney Health Dis 3:2054358116675343. https://doi.org/10.1177/2054358116675343
Doria A, Galecki A, Spino C, Mauer M (2019) Preventing early renal loss in diabetes (PERL) study: outcome of a 3-year trial of serum uric acid reduction with allopurinol. J Am Soc Nephrol (Kidney Week Abstract Supplement)
Faulkner J, Pye C, Al-Shabrawey M, Elmarakby AA (2015) Inhibition of 12/15-lipoxygenase reduces renal inflammation and injury in streptozotocin-induced diabetic mice. J Diabetes Metab. https://doi.org/10.4172/2155-6156.1000555
Eid AA, Gorin Y, Fagg BM et al (2009) Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 58(5):1201–1211. https://doi.org/10.2337/db08-1536
Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318(20):1315–1321. https://doi.org/10.1056/NEJM198805193182007
Dimitropoulos A, Rosado CJ, Thomas MC (2020) Dicarbonyl-mediated AGEing and diabetic kidney disease. J Nephrol. https://doi.org/10.1007/s40620-020-00718-z
Monnier VM, Bautista O, Kenny D et al (1999) Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48(4):870–880. https://doi.org/10.2337/diabetes.48.4.870
Giardino I, Edelstein D, Brownlee M (1996) BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 97(6):1422–1428. https://doi.org/10.1172/JCI118563
Sima AV, Botez GM, Stancu CS, Manea A, Raicu M, Simionescu M (2010) Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress. J Cell Mol Med 14(12):2790–2802. https://doi.org/10.1111/j.1582-4934.2009.00933.x
Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280(5):E685–694. https://doi.org/10.1152/ajpendo.2001.280.5.E685
Flyvbjerg A, Denner L, Schrijvers BF et al (2004) Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53(1):166–172. https://doi.org/10.2337/diabetes.53.1.166
Degenhardt TP, Alderson NL, Arrington DD et al (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61(3):939–950. https://doi.org/10.1046/j.1523-1755.2002.00207.x
Lassila M, Seah KK, Allen TJ et al (2004) Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15(8):2125–2138. https://doi.org/10.1097/01.ASN.0000133025.23732.46
Watson AM, Gray SP, Jiaze L et al (2012) Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 61(8):2105–2113. https://doi.org/10.2337/db11-1546
Lewis EJ, Greene T, Spitalewiz S et al (2012) Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 23(1):131–136. https://doi.org/10.1681/ASN.2011030272
Freedman BI, Wuerth JP, Cartwright K et al (1999) Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). Control Clin Trials 20(5):493–510. https://doi.org/10.1016/s0197-2456(99)00024-0
Pickering RJ, Tikellis C, Rosado CJ et al (2019) Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. J Clin Invest 129(1):406–421. https://doi.org/10.1172/JCI99987
Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Esposito K (2019) Type 2 diabetes and the kidney: insights from cardiovascular outcome trials. Diabetes Obes Metab 21(8):1790–1800. https://doi.org/10.1111/dom.13743
Bethel MA, Mentz RJ, Merrill P et al (2018) Renal outcomes in the EXenatide study of cardiovascular event lowering (EXSCEL). Diabetes 67(Supplement 1):522-P. https://doi.org/10.2337/db18-522-P
Mann JFE, Orsted DD, Brown-Frandsen K et al (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377(9):839–848. https://doi.org/10.1056/NEJMoa1616011
Muskiet MHA, Tonneijck L, Huang Y et al (2018) Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 6(11):859–869. https://doi.org/10.1016/S2213-8587(18)30268-7
Vilsbøll T, Gumprecht J, Silver RJ, Hansen T, Pettersson J, Wilding JP (2018) Semaglutide treatment and renal function in the SUSTAIN 6 trial. Diabetes 67(Supplement 1):1084-P. https://doi.org/10.2337/db18-1084-P
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519–1529. https://doi.org/10.1016/S0140-6736(18)32261-X
Fujita H, Morii T, Fujishima H et al (2014) The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85(3):579–589. https://doi.org/10.1038/ki.2013.427
Kodera R, Shikata K, Kataoka HU et al (2011) Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54(4):965–978. https://doi.org/10.1007/s00125-010-2028-x
Sourris KC, Yao H, Jerums G, Cooper ME, Ekinci EI, Coughlan MT (2016) Can targeting the incretin pathway dampen RAGE-mediated events in diabetic nephropathy? Curr Drug Targets 17(11):1252–1264. https://doi.org/10.2174/1389450116666150722141418
Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334. https://doi.org/10.1056/NEJMoa1515920
Perkovic V, de Zeeuw D, Mahaffey KW et al (2018) Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 6(9):691–704. https://doi.org/10.1016/S2213-8587(18)30141-4
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389
Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. https://doi.org/10.1056/NEJMoa1811744
Cannon CP, Perkovic V, Agarwal R et al (2020) Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c < 7%: results from the CREDENCE trial. Circulation 141(5):407–410. https://doi.org/10.1161/CIRCULATIONAHA.119.044359
Maeda S, Matsui T, Takeuchi M, Yamagishi S (2013) Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev 29(5):406–412. https://doi.org/10.1002/dmrr.2407
Ishibashi Y, Matsui T, Yamagishi S (2016) Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res 48(3):191–195. https://doi.org/10.1055/s-0035-1555791
Leng W, Ouyang X, Lei X et al (2016) The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-/-) mice. Mediators Inflamm 2016:6305735. https://doi.org/10.1155/2016/6305735
Maki T, Maeno S, Maeda Y et al (2019) Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: a possible role of SGLT2 in mesangial cells. Sci Rep 9(1):4703. https://doi.org/10.1038/s41598-019-41253-7
Yamamoto M, Kensler TW, Motohashi H (2018) The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol Rev 98(3):1169–1203. https://doi.org/10.1152/physrev.00023.2017
Chan K, Han XD, Kan YW (2001) An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci USA 98(8):4611–4616. https://doi.org/10.1073/pnas.081082098
Kovac S, Angelova PR, Holmstrom KM, Zhang Y, Dinkova-Kostova AT, Abramov AY (2015) Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim Biophys Acta. https://doi.org/10.1016/j.bbagen.2014.11.021
Zheng H, Whitman SA, Wu W et al (2011) Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60(11):3055–3066. https://doi.org/10.2337/db11-0807
de Zeeuw D, Akizawa T, Audhya P et al (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369(26):2492–2503. https://doi.org/10.1056/NEJMoa1306033
Tan SM, Sharma A, Stefanovic N et al (2014) Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes 63(9):3091–3103. https://doi.org/10.2337/db13-1743
Yang S, Zheng Y, Hou X (2019) Lipoxin A4 restores oxidative stress-induced vascular endothelial cell injury and thrombosis-related factor expression by its receptor-mediated activation of Nrf2-HO-1 axis. Cell Signal 60:146–153. https://doi.org/10.1016/j.cellsig.2019.05.002
Brennan EP, Mohan M, McClelland A et al (2018) Lipoxins regulate the early growth response-1 network and reverse diabetic kidney disease. J Am Soc Nephrol 29(5):1437–1448. https://doi.org/10.1681/ASN.2017101112
De Haan JB, Crack PJ, Flentjar N, Iannello RC, Hertzog PJ, Kola I (2003) An imbalance in antioxidant defense affects cellular function: the pathophysiological consequences of a reduction in antioxidant defense in the glutathione peroxidase-1 (Gpx1) knockout mouse. Redox Rep 8(2):69–79. https://doi.org/10.1179/135100003125001378
Tan SM, Sharma A, Stefanovic N, de Haan JB (2015) Late-intervention study with ebselen in an experimental model of type 1 diabetic nephropathy. Free Radic Res 49(3):219–227. https://doi.org/10.3109/10715762.2014.993628
Sourris KC, Harcourt BE, Tang PH et al (2012) Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med 52(3):716–723. https://doi.org/10.1016/j.freeradbiomed.2011.11.017
Bolignano D, Cernaro V, Gembillo G, Baggetta R, Buemi M, D’Arrigo G (2017) Antioxidant agents for delaying diabetic kidney disease progression: a systematic review and meta-analysis. PLoS One 12(6):e0178699. https://doi.org/10.1371/journal.pone.0178699
Lonn E, Yusuf S, Hoogwerf B et al (2002) Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25(11):1919–1927. https://doi.org/10.2337/diacare.25.11.1919
Yang Y, Wang H, Kouadir M, Song H, Shi F (2019) Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis 10(2):128. https://doi.org/10.1038/s41419-019-1413-8
Shahzad K, Bock F, Dong W et al (2015) Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int 87(1):74–84. https://doi.org/10.1038/ki.2014.271
Coll RC, Robertson AA, Chae JJ et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21(3):248–255. https://doi.org/10.1038/nm.3806
Zhang C, Zhu X, Li L et al (2019) A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation. Diabetes Metab Syndr Obes 12:1297–1309. https://doi.org/10.2147/DMSO.S199802
Jiang H, He H, Chen Y et al (2017) Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med 214(11):3219–3238. https://doi.org/10.1084/jem.20171419
Huang Y, Jiang H, Chen Y et al (2018) Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. https://doi.org/10.15252/emmm.201708689
Tan SM, Zhang Y, Cox AJ, Kelly DJ, Qi W (2011) Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy. Nephrol Dial Transp 26(1):100–110. https://doi.org/10.1093/ndt/gfq355
Marchetti C, Swartzwelter B, Gamboni F et al (2018) OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci USA 115(7):E1530–E1539. https://doi.org/10.1073/pnas.1716095115
Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131. https://doi.org/10.1056/NEJMoa1707914
Ridker PM, MacFadyen JG, Glynn RJ et al (2018) Inhibition of INterleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol 71(21):2405–2414. https://doi.org/10.1016/j.jacc.2018.03.490
Reutens AT, Jandeleit-Dahm K, Thomas M et al (2019) A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: protocol and statistical considerations. Contemp Clin Trials. https://doi.org/10.1016/j.cct.2019.105892
Bolton WK, Cattran DC, Williams ME et al (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24(1):32–40. https://doi.org/10.1159/000075627
Tavafi M (2013) Diabetic nephropathy and antioxidants. J Nephropathol 2(1):20–27. https://doi.org/10.5812/nephropathol.9093
Chew P, Yuen DY, Stefanovic N et al (2010) Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. Diabetes 59(12):3198–3207. https://doi.org/10.2337/db10-0195
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest regarding the present article.
Ethical approval
Ethical approval for this review study was not required and includes no experiments.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Østergaard, J.A., Cooper, M.E. & Jandeleit-Dahm, K.A.M. Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease. J Nephrol 33, 917–929 (2020). https://doi.org/10.1007/s40620-020-00749-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-020-00749-6